Altimmune (ALT) Short term Debt (2012 - 2022)

Altimmune (ALT) reported Short term Debt of $4.3 million for Q1 2022, down 29.23% quarter-over-quarter from $6.1 million in Q4 2021.

Altimmune (ALT) Short term Debt (2012 - 2022) Analysis & Trends

Altimmune (ALT) has 6 years of Short term Debt data on file, last reported at $4.3 million in Q1 2022.

Short term Debt for Q1 2022 came in at $4.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $4.3 million (changed N/A YoY), and the FY2021 annual result was $6.1 million, changed N/A from the prior year.
Short term Debt eased to $4.3 million in Q1 2022 per ALT's latest filing, from $6.1 million in the prior quarter.
Over five years, Short term Debt peaked at $6.1 million in Q4 2021 and troughed at $4.3 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Altimmune	336.67 Mn	336.67 Mn	-

Download Data